top of page

KRAS Cancer News & Updates



Val: A Life of Courage, Faith, and Hope
Val’s Advice to Others Facing Lung Cancer
...a quiet but powerful advocate, offering guidance to other people, especially young adults with cancer:
“Don’t freak out when you’re diagnosed. And don’t go straight to Google. Statistics don’t define you
KRAS Cancer Connect
Jul 29, 2025


Why AML Treatments Don’t Always Work—and What This Study Reveals About KRAS, NPM1, and Monocytic Resistance
By KRAS Kickers – Cancer Knowledge + Research + Advocacy = Survivorship 📅 May 2025 | 🧬 Published in Blood Cancer Discovery 🔬...

Terri Conneran KRAS Kickers
May 22, 2025


LGSOC Cancer Treatment FDA Fast Tracked
Low-Grade Serous Ovarian Cancer (LGSOC) is a rare, slow-growing type of ovarian cancer. It starts in the cells lining the ovaries, fallopian tubes, or peritoneum ...

Terri Conneran KRAS Kickers
May 8, 2025


Lung & Pancreatic cancer Patient Knowledge of Research
KRAS Kickers is a cancer patient-led nonprofit organization that shares Knowledge of publicly available Research to empower patients and caregivers to Advocate for Survivorship.
Our goal to kick cancer's KRAS!

Terri Conneran KRAS Kickers
May 7, 2025


Essential Guide to Cancer Biomarkers For Cancer Patients
Need to know what mutation is driving the cancer bus. It's different than noise from the back of the bus.
Biomarkers testing tells us what to Aim for as the cancer driver, not the background noise. Taking out the cancer driver can make the difference.
Biomarkers provide the insights as to what is driving the cancer.

Terri Conneran KRAS Kickers
Apr 22, 2025


NEW combination trial arm of RMC-9805 plus RMC-6236
Changes to KRAS G12D trial - July 23, 2024 The monotherapy arm of RMC-9805 - RAS(ON) inhibitor now includes info on the combination arm...
fireflyannf
Apr 7, 2025


Black Diamond trial of BDTX-4933
A Phase 1 Study of BDTX-4933 in Patients With BRAF and Select RAS/MAPK Mutation Positive Cancers Brief Summary: "BDTX-4933-101 is a...
fireflyannf
Apr 7, 2025


KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer
" Phase 2 study evaluating the efficacy and immune response to a synthetic long peptide mutant KRAS vaccine (SPL mKRASvax) combined with...
fireflyannf
Apr 7, 2025
Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS
PHASE 1 trial: Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS At MD...
fireflyannf
Apr 7, 2025


A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects with Solid Tumors
Phase 1 trial, 230 patients Trial opened April 2024 in Australia Expanded to US Locations in September 2024 “ Brief Summary This is a...
fireflyannf
Apr 7, 2025


PROSPER trial for KRAS G12C mutations
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors (PROSPER) Phase 1/2 - 403 patients to enroll Opened in...
fireflyannf
Apr 7, 2025
Getting ahold of KRAS Science: Visiting Kevan Shokat at his UCSF Lab
By the time I met Kevan Shokat, KRAS G12D was already the name of the devil my body was fighting.
Then Kevan did something extraordinary. He made me a three dimensional model of KRAS, had it painted, and sent it to me with a handwritten letter.
How KRAS Became Druggable: Kevan Shokat and the Pocket That Opened a New Era of RAS Drugs
more than 60 additional drugs targeting the RAS family are now in development. What began with a chemical foothold in KRAS G12C has become an expanding field of RAS drug discovery. Why This Matters for People With KRAS Cancer The science also explains why knowing the exact KRAS variant matters.
Where can patients find the NCCN guidelines used to guide cancer treatment?
NCCN Guidelines help clinicians determine what evaluations are appropriate, which treatment options are supported by current evidence, when additional testing may be important, and how care may change as a cancer changes.For patients, NCCN offers a version for patients.

bottom of page
